Pertuzumab
- Generic Name
- Pertuzumab
- Brand Names
- Perjeta, Perjeta-Herceptin, Phesgo
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 380610-27-5
- Unique Ingredient Identifier
- K16AIQ8CTM
- Background
Pertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (subdomain II) of the human epidermal growth factor receptor 2 protein (HER2). It consists of two heavy chains and two lights chains that have 448 and 214 residues respectively. It was first approved by the FDA in 2012 for use with docetaxel and anoth...
- Indication
Pertuzumab is indicated for intravenous administration in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. It is also indicated in combination with trastuzumab and other chemotherapies for the neoadjuvant t...
- Associated Conditions
- Inflammatory Breast Cancer (IBC), Locally Advanced Breast Cancer (LABC), Metastatic Breast Cancer, Stage I Breast Cancer
- Associated Therapies
- -
A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Advanced Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-10-27
- Last Posted Date
- 2018-08-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 30
- Registration Number
- NCT01461057
- Locations
- 🇨🇿
Fakultni nemocnice Olomouc; Onkologicka klinika, Olomouc, Czechia
🇧🇪UZ Leuven Gasthuisberg, Leuven, Belgium
🇮🇹Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2, Milano, Lombardia, Italy
A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-05-24
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 4804
- Registration Number
- NCT01358877
- Locations
- 🇺🇸
Texas Oncology - DFW, Dallas, Texas, United States
🇺🇸The Mark H. Zangmeister Ctr; Mid Ohio Onc/Hem Inc., Columbus, Ohio, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers
- Conditions
- Interventions
- First Posted Date
- 2010-05-12
- Last Posted Date
- 2016-02-05
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 43
- Registration Number
- NCT01121939
- Locations
- 🇺🇸
Hematology-Oncology Associates of Northern NJ, Morristown, New Jersey, United States
🇺🇸Florida Hospital Cancer Institute, Orlando, Florida, United States
🇺🇸Grand Rapids Oncology Program, Grand Rapids, Michigan, United States
A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)
- Conditions
- Interventions
- First Posted Date
- 2010-05-10
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1095
- Registration Number
- NCT01120184
- Locations
- 🇹🇭
Faculty of Med. Siriraj Hosp.; Med.-Div. of Med. Oncology, Bangkok, Thailand
🇹🇷Gazi Uni Medical Faculty Hospital; Oncology Dept, Ankara, Turkey
🇬🇧Bristol Haematology and Oncology centre, Bristol, United Kingdom
A Phase 2 Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma
- First Posted Date
- 2010-04-22
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- George Albert Fisher
- Target Recruit Count
- 1
- Registration Number
- NCT01108458
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-01-13
- Last Posted Date
- 2016-01-29
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 283
- Registration Number
- NCT01048099
- Locations
- 🇺🇸
Center for Cancer and Blood Disorders, Fort Worth, Texas, United States
🇺🇸Florida Cancer Specialists, St. Petersburg, Florida, United States
🇺🇸Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States
A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)
- Conditions
- Interventions
- First Posted Date
- 2009-12-04
- Last Posted Date
- 2018-08-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 452
- Registration Number
- NCT01026142
- Locations
- 🇧🇪
UZ Brussel, Brussel, Belgium
🇭🇰Queen Mary Hospital; Surgery, Hong Kong, Hong Kong
🇷🇺Semashko Central Clinical Hospital; Dept of Chemotherapy, Moscow, Russian Federation
A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-09-15
- Last Posted Date
- 2017-02-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 225
- Registration Number
- NCT00976989
A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
- First Posted Date
- 2009-07-27
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- Pamela L. Kunz
- Target Recruit Count
- 4
- Registration Number
- NCT00947167
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
A Study of Trastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Participants With Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-07-08
- Last Posted Date
- 2017-04-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 98
- Registration Number
- NCT00934856
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.